Loading...
XSHG
600267
Market cap1.74bUSD
Dec 05, Last price  
10.60CNY
1D
-0.38%
1Q
-0.28%
Jan 2017
-19.39%
IPO
146.96%
Name

Zhejiang Hisun Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:600267 chart
P/E
20.51
P/S
1.26
EPS
0.52
Div Yield, %
Shrs. gr., 5y
3.67%
Rev. gr., 5y
-2.44%
Revenues
9.79b
-5.65%
1,905,870,4132,261,985,6062,838,770,7413,181,978,2634,003,470,4374,544,508,9595,161,394,2145,801,766,0628,604,311,58310,096,747,8628,767,428,1409,733,423,46010,571,526,72310,187,440,96511,071,784,24211,354,395,74312,136,465,76512,036,690,08110,373,071,9569,786,848,052
Net income
601m
115,876,71280,338,876139,672,066195,320,954272,250,101365,761,620504,081,307301,289,979301,857,409307,896,70613,566,704013,566,2260323,265,742723,167,293486,888,358488,860,0510601,182,827
CFO
2.11b
+39.39%
113,527,315108,028,871437,720,980221,276,654472,846,967509,179,184525,312,010375,746,180527,249,352571,038,090736,168,523775,899,3371,240,708,2471,446,308,104698,388,3711,589,608,7561,736,524,2432,065,736,6081,516,960,5452,114,532,552
Dividend
May 19, 20230.17 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang Hisun Pharmaceutical Co., Ltd. manufactures and supplies pharmaceutical products in China. It provides active pharmaceutical ingredients and finished dosage form products. The company offers products in the areas of anti-tumor, cardiovascular, anti-infective, liver care, orthopedics, anticancer, anti-parasitic, immunosuppressant, etc.; and weight loss, anti-viral, anti-TB, veterinary pharma, and others. It also provides product consultation and CMO/CRO manufacturing services. The company was founded in 1956 and is headquartered in Taizhou, China.
IPO date
Jul 25, 2000
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT